^
BIOMARKER:
EGFR mutation
i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR mutation
NSCLC
EGFR inhibitor
Sensitive
:
A2
Oncol Res Treat - 4d
EGFR mutation
NSCLC
osimertinib
Sensitive
:
A2
Asia Pac J Clin Oncol - 1wk
EGFR mutation
NSCLC
erlotinib + ramucirumab
Sensitive
:
A2
Cancer Treat Res Commun - 2wk
EGFR mutation
NSCLC
pembrolizumab
Sensitive
:
A1
Front Oncol - 3wk
EGFR mutation
NSCLC
bevacizumab
Sensitive
:
A2
J Formos Med Assoc - 3wk
EGFR mutation
NSCLC
gefitinib
Sensitive
:
A1
EGFR mutation
NSCLC
afatinib
Sensitive
:
A1
EGFR mutation
NSCLC
erlotinib
Sensitive
:
A1
EGFR mutation
NSCLC
bevacizumab + atezolizumab
Sensitive
:
A1
EGFR mutation
NSCLC
dacomitinib
Sensitive
:
A1
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + erlotinib
Sensitive
:
A1
EGFR mutation
NSCLC
atezolizumab
Sensitive
:
A1
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive
:
A1
EGFR mutation
NSCLC
nivolumab + ipilimumab
Sensitive
:
A2
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
gefitinib
Sensitive
:
A2
EGFR mutation
NSCLC
bevacizumab + erlotinib
Sensitive
:
A2
EGFR mutation
NSCLC
icotinib
Sensitive
:
A2
EGFR mutation
LUAD
gefitinib
Sensitive
:
B
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
osimertinib
Sensitive
:
B
EGFR mutation
NSCLC
Tyrosine kinase inhibitor
Sensitive
:
B
EGFR mutation
Lung Cancer
Tyrosine kinase inhibitor
Sensitive
:
B
EGFR mutation
LUAD
afatinib
Sensitive
:
B
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive
:
B
EGFR mutation
Lung Non-Small Cell Squamous Cancer
bevacizumab
Sensitive
:
B
EGFR mutation
Solid Tumor
BDTX-189
Sensitive
:
B
EGFR mutation
NSCLC
nivolumab
Resistant
:
B
EGFR mutation
GBM
erlotinib
Sensitive
:
C1
EGFR mutation
Esophageal Squamous Cell Carcinoma
afatinib
Sensitive
:
C1
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
erlotinib
Sensitive
:
C1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our